Cannabis to be Rescheduled to Schedule 3

Sources within the administration have confirmed that the DEA will agree with the recommendation that Health and Human Services and the FDA made last year to reclassify cannabis from where we are currently Schedule 1 (along with heroin)  to the much more appropriate Schedule 3 (ketamine, testosterone, Tylenol with codeine).

The HHS and FDA compiled an exhaustive report reviewing all the research studies over a year. They found that more than 30,000 clinicians recommended cannabis for over a million and a half patients for more than 15 conditions. Those of us who work with patients using cannabis can attest that when it is used appropriately and with the right guidance, it is an extremely safe and effective form of medicine.

This change in scheduling will also make it much easier to study cannabis and push forward the science of how it works – as the hurdles to studying it as a Schedule 1 substance were enormous.

It will also help alleviate some of the horrendous consequences that people have faced merely for consuming cannabis. So many lives and families were torn apart by a law that had no rational scientific basis and should never have been applied in the first place.

We here at Plesio Health have been waiting for over eight months for this announcement, and we couldn’t be more excited. This move will allow for many, many more people who are suffering from chronic and hard-to-treat conditions – many of whom are currently not getting relief with traditional pharmaceuticals and are being exposed to significant risks that come with medications like opiates and benzodiazepines. While cannabis should never have been classified as Schedule One in the first place, we are so happy to see that the administration is following the science, listening to patients, and doing the right thing. – Your Friends at Plesio Health

Scroll to Top